Children with acute myelogenous leukemia (AML) have a high risk of infectious complications which might be reduced by prophylactic granulocyte colony-stimulating factor (G-CSF). However, G-CSF could induce AML blast proliferation. The prospective randomized trial AML-BFM 98 investigated the impact of G-CSF on hematopoetic recovery and infectious complications (primary endpoints) and on outcome (secondary endpoint) in children (0-18 years) with de novo AML. Patients with >5% blasts in day 15 bone marrow or with FAB M3 were not included. Between 1998 and 2003, 161 children with AML were randomized to receive G-CSF after induction 1 and 2, whereas 156 patients were assigned to the control group. Time of neutropenia after induction 1 and 2 was significantly shorter in the G-CSF group (23 vs 18 and 16 vs 11 days, P=.02 and .001, respectively). G-CSF did not decrease the incidence of febrile neutropenia (72/36 vs 78/37), microbiologically-documented infections (27/25 vs 36/19) and infection-associated mortality (5 vs 2). Both groups had similar 5-year-EFS (59±4% vs 58±4%). Since G-CSF does not influence the risk of infectious complications or outcome in children undergoing therapy for AML, one can not advocate the routine use of G-CSF in this patient group.
Introduction
Therapy for acute myelogenous leukemia (AML) is one of the most intensive treatment modalities in pediatric oncology. It has been shown that the majority of patients experience one or more infectious complications during treatment, which occur in particular during chemotherapy-induced neutropenia. 1 Strategies to reduce therapy-associated toxicity have involved the use of hematopoietic growth factors, such as granulocyte-colony stimulating factor (G-CSF). This hematopoietic growth factor expands circulating pools of neutrophils by stimulating proliferation and maturation of myeloid progenitor cells and additionally enhances phagocyte function ex vivo. 2, 3 Multiple clinical trials in pediatric cancer patients have demonstrated that G-CSF shortens duration of neutropenia, 4 but this has not necessarily translated into a demonstrable reduction of risk for infection, and data supporting a positive effect of G-CSF on overall survival are conflicting. 4 The guidelines published by the American Society of Clinical Oncology (ASCO) suggest that the costly hematopoietic growth factors should be used as primary prophylaxis only when the expected incidence of febrile neutropenia is 40% or more. 5 This recommendation is supported by a recent meta-analysis which demonstrated that the use of G-CSF in this group of patients was associated with reduction in febrile neutropenia by 20%. 6 On the other hand, the prophylactic administration of G-CSF in patients with AML has been a matter of controversy, since most of the myeloid leukemia cells express receptors for G-CSF, and G-CSF has been shown to induce proliferation of leukemic blasts in vitro. 7, 8 Whereas a number of randomized clinical trials in adult patients with AML demonstrated that administration of G-CSF had some clinical benefit without worsening overall survival, 9-16 randomized studies in the pediatric population are lacking to date. In this report, we present the results of a mulicenter randomized trial
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Patients and Methods

Clinical trial AML-BFM 98:
This study was part of the prospective clinical trial AML-BFM 98, which has been described in detail elsewhere. 17 Children up to the age of 18 years with newly diagnosed AML were eligible for the study. Patients with AML and Down syndrome were treated as protocol patients and were randomized, but received less anthracyclines and no second induction. Patients were enrolled between July 1 st 1998 and June 30 th 2003 . The protocol was approved by the protocol review committee of the German Cancer Society, and by the ethics committee of the University of Münster. Each patient (or parent) had to sign an informed consent before inclusion into the study and separately for the randomizations. All initial smears and day 15 bone marrow aspirates were centrally reviewed at the University Children's Hospital in Münster.
In brief, the treatment plan consisted of the 8-day AIE induction (cytarabine 100 mg/m 2 /day continuous infusion on day 1 and 2 followed by a 30 min infusion every 12 hours on days 3-8, idarubicin 12 mg/m 2 on days 3, 4, 5 and etoposide 150 mg/m 2 on days 6, 7, 8, and intrathecal cytarabine on days 0 and 8). A second induction therapy (HAM: high-dose cytarabine 3 g/m 2 every 12 hours for 3 days, mitoxantrone 10 mg/m 2 on days 4 and 5 and intrathecal cytarabine day 6) was given to all patients, except to those with FAB M3 and to patients with Down syndrome. After induction therapy, patients were randomly assigned to receive either standard consolidation therapy (6-thioguanine, prednisolone, vincristine, cytarabine, idarubicin cyclophosphamide) or a 2-cycle consolidation with AI (cytarabine and idarubicin) and haM (high-dose cytarabine and mitoxantrone). Consolidation therapy was followed by one intensification block (HAE: high-dose cytarabine and etoposide), followed by cranial irradiation and maintenance therapy (thioguanine and cytarabine). Auer rods and FAB M4eo with <5% blasts on day 15 in the bone marrow, FAB M3 independent of blast count on day 15; high risk (HR): all others) were not eligible for stem cell transplantation (SCT), allogeneic SCT was recommended for HR patients if they had an HLA-identical sibling.
All patients except those with more than 5% blasts in the bone marrow on day 15 and those with FAB M3 were eligible for randomization regarding G-CSF performed on day 15. The hematopoietic growth factor was administered at a dosage of 5µg/kg/day either subcutaneously or as an intravenous infusion over at least 1 hour. Based on the data of a randomized trial evaluating the optimal schedule for administering G-CSF in chemotherapyinduced neutropenia, the initiation of the growth factor began day 15 after the start of AIE and HAM, respectively, and continued until the absolute neutrophil count exceeded 500/µl on three consecutive days.
18
Prophylaxis and treatment of infectious complications were performed according to common standards.
19,20 Empirical broad-spectrum antibiotics were started in case of fever, and systemic antifungal therapy was given for suspected or documented fungal infection or was started when fever persisted despite antibiotic therapy. All except seven patients eligible for randomization had central venous access devices.
Statistical methods and definitions:
Randomization was centrally performed using the permuted block method. Patients were stratified according to risk groups. According to the results from previous AML-BFM studies, the rate of severe infections was estimated to be 30%; 135 patients per group had to be randomized to receive or not to receive G-CSF to 
Results
Patients: Four-hundred-twenty-nine out of a total of 538 patients (473 patient without and 65 patients with Down syndrome) treated according to the multicenter clinical trial AML-BFM 98 were eligible for randomization; 15 patients died within the first 9 days after the start of treatment, 28 patients had the FAB M3 subtype and 66 patients had more than 5% blast in the bone marrow on day 15. The characteristics of randomized patients were similar to those of the study patients. Hundred-sixty-one children were randomized to the G-CSF group, whereas 156 patients were assigned to the control group which did not receive the hematopoietic growth factor ( Table 1 ). The groups were well balanced for age, FAB subtype, initial leukocyte count, cytogenetic analysis, Down syndrome, and risk groups. Significantly more boys were randomized to receive G-CSF ( Table 1 ). The compliance with treatment allocation was 90%; 18 patients assigned to the group without G-CSF received the hematopoietic growth factor, whereas 14 patients randomized for G-CSF did not receive it. The characteristics of patients randomized (intent-to-treat) was comparable to the characteristics of patients who were treated as assigned (data not shown). Median follow-up of patients alive was 4.1 years (range 1.3-7.1). Twenty-seven of the randomized patients underwent SCT in first remission.
Hematologic recovery: Neutrophil recovery after both AIE and HAM was significantly shorter in the G-CSF group than in patients of the control group (intent-to-treat analysis: median, 23.0 vs 18.0 days, P=.02, and 16.0 vs 11.0 days, P=.001, respectively; Table 2 ). This difference was seen in particular in HR patients (median, 24.0 vs 18 days, P=.03, and 15.5 vs 11.0, P=.008, respectively). The hematopoietic growth factor did not affect the time of platelet recovery (Table 2) . Similarly, the administration of G-CSF after induction therapy had no impact on hematologic recovery after consolidation therapy and after HAE (data not shown).
Infectious complications:
Infection-associated mortality and the incidence of life-threatening sepsis during induction therapy did not differ between the G-CSF and control group (intentto-treat analysis: 5 vs 2 patients and 1 vs 5 patients, P=.45 and P=.12, respectively) ( Table 3) including coagulase-negative staphylococci (CoNS) (n=5)] and viridans group streptococci (VGS) (6) , and 12 Gram-negative organisms, among them Escherichia coli (3), Pseudomonas aeruginosa (2), and Klebsiella spp (2). In addition, Candida spp was isolated from the blood from 3 patients who received G-CSF. In the control group, 36 Gram-positive isolates, mainly staphylococci (8; including 6 CoNS) and streptococci (18; including 16 VGS), and 9 Gramnegative pathogens, including Pseudomonas aeruginosa (3), Escherichia coli (1), Klebsiella spp (1), and Enterobacter spp (1) were recovered from the blood. Invasive fungal infection occurred in a total of 4 patients: 1 patient suffered from invasive Aspergillosis of the sinus, and Candida spp was isolated from the blood of 3 patients; all these patients were assigned to the G-CSF group and also received the hematopoietic growth factor (treated-as-assigned).
Patients of the G-CSF group and control group had a comparable risk to suffer from febrile neutropenia without having a source identified (FUO). Specifically, FUO occurred in AIE in 78 patients with G-CSF (52.7%) vs 72 patients without G-CSF (51.4%; P=.91) and in HAM in 37 patients of the G-CSF group (30.8%) vs 36 patients of the control group (29.8%; P=.89) ( Table 3 ). In addition, the number of febrile days was not significantly reduced by the administration of G-CSF (Table 3) as it was the fact regarding the use of antifungal agents (data not shown).
Toxicities:
The administration of G-CSF had no impact on the incidence of oral and pharyngeal mucositis grade 3 and 4 after both induction chemotherapies [intent-to-treat analysis: 38 (26.6%) and 8 (6.9%) of patients with G-CSF vs 33 (23.6%) and 6 (5.2%) of patients without G-CSF, P=.59 each]. Similarly, no significant difference between the G-CSF and control group were seen regarding diarrhea, nausea, vomiting, hepatic and cardiovascular abnormalities (data not shown).
Outcome: In total, 154 (95.7%) patients in the G-CSF group and 149 (95.5%) patients in the control group achieved CR (intent-to-treat analysis: P=1.0) (Table 4) . Similarly, G-CSF had no impact on the CR rates of the different subgroups analyzed (Table 4 ). In addition, G-CSF did not influence the cumulative incidence of relapse at 5 years, 5-year-EFS and the risk of death in CCR at 5 years in the total patient group and in the different subgroups analyzed (Table 5) . 29 Our results, however, are in contrast to a meta-analysis of randomized controlled trials which evaluated the effect of prophylactic hematopoietic growth factors in children undergoing intensive therapy for different types of cancer resulting in an incidence of febrile neutropenia ≥ 40%. 6 The analysis demonstrated that the prophylactic administration of G-CSF or GM-CSF led to a reduction of febrile neutropenia by 20%. Since the treatment regimen in the presented clinical trial resulted in an incidence of febrile neutropenia even higher than 40%, the number of randomized patients is large enough to detect a potential benefit of prophylactic G-CSF with a high probability. It only can be Although it has been shown that AML blast cells have G-CSF receptors and that G-CSF could increase the kinetics of leukemia cell growth, 7, 8 we and others 9-16,27,29 did not observe a significant impact of prophylactic G-CSF on long-term outcome of patients with AML (Table   5 ). It has to be mentioned, however, that all but one 9-16,27,29 of these studies enrolled predominantly adult patients older than 40 years. On the other hand, we recognize that our study was not sufficiently powered to address this question. Given a baseline of 60% probability of 5-years EFS, a difference of about 15% could have been detected with the actual sample size (power 80%, alpha 5%, two-sided test). Our results indicate that the CR rate was not affected by the administration of G-CSF, an observation which was also made in most of the trials in adult AML (Table 5) . 9,11,12,14,15,27 In contrast, Alonzo et al reported that pediatric patients with hypercellular day 7 marrow who received G-CSF had a higher remission rate than children who did not receive G-CSF. 29 This fact might be explained by the timing of G-CSF administration which began 2 days after completion of the first cycle of chemotherapy and continued through the second cycle. Similarly, a recent trial in adult AML indicated that G-CSF administered concomitantly with standard induction chemotherapy results in a higher CR rate than chemotherapy alone. 16 In contrast to a retrospective analysis of 22 consecutive pediatric patients undergoing autologous bone marrow transplantation for treatment of primary AML which showed that the 12 patients who received GM-CSF as part 
